Development asset linked to Krystal Biotech Netherlands in public FDA and regional records.
biotech · Dystrophic Epidermolysis Bullosa · Autosomal Recessive Ichthyosis · KRYS
Krystal Biotech Netherlands
Krystal Biotech Netherlands B.V.
Krystal Biotech Netherlands drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, US HQ
2016 Founded
306 Employees
Public company Type
KRYS · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, US
- Founded
- 2016
- Employees
- 306
- Programs
- 14
- Drugs
- 7
- Patents
- 14
Krystal Biotech Netherlands pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Krystal Biotech Netherlands drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
beremagene geperpavec
Dermatologicals (D03)Dermatologicals (D03) compound in Krystal Biotech Netherlands's portfolio. Molecular target: Collagen alpha-1(VII) chain.
- Target
- Collagen alpha-1(VII) chain
- Mechanism
- Collagen alpha-1(VII) chain exogenous gene
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
dodecafluoropentane
Various (V08)Various (V08) compound in Krystal Biotech Netherlands's portfolio. Mechanism: Ultrasound contrast agent.
- Mechanism
- Ultrasound contrast agent
-
epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Krystal Biotech Netherlands in public FDA and regional records.